361 Capital’s Array Biopharma Inc ARRY Stock Holding History

361 Capital’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,258	Closed	-$253K	–	313
2017 Q2	$253K	Buy	30,258 +14,480	+92%	+$118K	0.04%	158
2017 Q1	$141K	Buy	+15,778	New	+$168K	0.03%	156

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

361 Capital's ARRY Position: Q3 2017 in Review

361 Capital sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 30,258 shares — an estimated $253K sold.

361 Capital first reported a position in ARRY in Q1 2017 and held it in 2 quarters. The position peaked at $253K in Q2 2017. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

361 Capital reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
361 Capital sold 30,258 Array Biopharma Inc shares in Q3 2017, an estimated $253K.
361 Capital first reported a position in Array Biopharma Inc in Q1 2017 and held it in 2 quarters.
361 Capital's Array Biopharma Inc position peaked at $253K in Q2 2017.
184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on 361 Capital's 13F filing for Q3 2017, filed 7 Nov 2017.